Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with Nonmyeloablative HCT for Advanced CLL
NCT00104858Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2004
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of rituximab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Fred Hutchinson Cancer Center. Started Dec 2004; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00104858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00104858.